- Home
- MPT vs ADRX Comparison
MPT vs ADRX Comparison
Compare MPT & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPT | ADRX |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2004 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MPT | ADRX |
|---|---|---|
| Price | $1.75 | $13.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $3.67 | ★ $34.25 |
| AVG Volume (30 Days) | ★ 20.0M | 357.8K |
| Earning Date | 10-29-2026 | 11-23-2026 |
| Dividend Yield | ★ 19.89% | N/A |
| EPS Growth | ★ 88.56 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $972,022,000.00 | N/A |
| Revenue This Year | N/A | $72.35 |
| Revenue Next Year | $6.73 | $570.74 |
| P/E Ratio | $36.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.80 | $12.50 |
| 52 Week High | $6.47 | $19.57 |
Technical Indicators
Market Signals| Indicator | MPT | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 13.37 | 28.75 |
| Support Level | N/A | N/A |
| Resistance Level | $5.24 | $19.01 |
| Average True Range (ATR) | 0.19 | 1.37 |
| MACD | -0.06 | -0.44 |
| Stochastic Oscillator | 2.15 | 21.31 |
Price Performance
Historical ComparisonAbout MPT Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.